Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
To assess the objective response rate (ORR: complete response + partial response [CR+ PR]) of
E7080 in subjects with unresectable endometrial cancer and disease progression following
platinum-based, first-line chemotherapy. .